Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
MT-2 vs. Semaglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
MT-2 is distinguished by a nonselective melanocortin agonist with tiny early human studies of pigmentation and erectile response. Unlike MT-1's SCENESSE implant, MT-2 has no FDA-approved product or indication; Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
MT-2 is distinguished in the current record by a nonselective melanocortin agonist with tiny early human studies of pigmentation and erectile response. Unlike MT-1's SCENESSE implant, MT-2 has no FDA-approved product or indication. Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceSemaglutide
MT-2: Very early human evidence. Semaglutide: Mature human evidence.
Regulatory historySemaglutide
MT-2: Not FDA approved. Semaglutide: FDA approved for defined product-specific indications.
Mechanistic breadthMT-2
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
MT-2
- Skin pigmentation
- Erectile response in men
- Sexual desire in men
- Vitiligo with narrowband UV-B — registered trial, no results
Semaglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Chronic kidney disease
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
MT-2Not FDA approved
Not FDA approved. FDA identifies potential significant safety risks for compounded MT-2, including immunogenicity from aggregation or peptide-related impurities and serious published adverse-event reports.
SemaglutideFDA-labeled indications
FDA approved in product-specific formulations for defined weight-management, type 2 diabetes, cardiovascular, kidney, and MASH indications.
Evidence depthEvidence, not a winner
MT-2Three tiny controlled studies
One three-person pigmentation Phase 1 pilot, two ten-person placebo-controlled erectile-response crossover studies, one 2026 registered Phase 2 vitiligo trial without results, and multiple safety case reports.
SemaglutideMature Phase 3 + outcomes
Multiple large Phase 3 programs and outcomes trials, including SELECT, FLOW, ESSENCE, STEP TEENS, and the higher-dose STEP UP program.
Weight outcomesEvidence, not a winner
MT-2No dedicated human evidence
No controlled human weight-loss or body-composition outcome trial was located. Reduced appetite appeared as a short-term adverse effect; weight claims are primarily preclinical or anecdotal.
SemaglutidePeer-reviewed Phase 3
STEP 1 reported −14.9% mean change at 68 weeks with 2.4 mg versus −2.4% placebo. STEP UP later reported −18.7% with 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
MT-2No dedicated evidence
No controlled human glucose-control or diabetes-outcomes study was located.
SemaglutideApproved + extensive trials
Approved injection and oral products have extensive type 2 diabetes evidence. Product names, routes, strengths, and label instructions are not automatically interchangeable.
Obstructive sleep apnoeaEvidence, not a winner
MT-2No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
SemaglutideNo approved indication
No FDA-approved semaglutide indication for obstructive sleep apnoea was identified in the current U.S. labels.
Cardiovascular outcomesEvidence, not a winner
MT-2No outcomes program
No cardiovascular outcomes program was located. Case reports describe serious systemic toxicity, renal injury or infarction, and ischemic priapism, but cannot estimate incidence.
SemaglutideSELECT + labeled uses
SELECT demonstrated fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. Other approved product labels cover defined diabetes populations.
Administration and handlingEvidence, not a winner
MT-2Historical study protocols only
Historical studies used monitored subcutaneous protocol exposures. MT-2 has no FDA-approved consumer dose, route, schedule, reconstitution method, or storage instructions.
SemaglutideMultiple product-specific labels
Current FDA labels include weekly subcutaneous injections and daily oral tablets with product-specific administration, switching, and storage instructions. Approved products require no reconstitution.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Long-term and repeated-use safety, risks across broader populations, and whether unregulated products match the studied compound.
- Long-term comparative outcomes across newer products and doses, rare events at population scale, and evidence outside studied populations or approved products.
Community Intelligence
Emerging patterns, clearly separated from evidence
MT-2
No community experiences yetBe the first account holder to contribute.
Semaglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.